The era of personalized medicine is already well established in oncology. Biomarker-driven targeted therapies are among the top-selling oncology products today, and the impact of molecular…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Last Updated 30 June 2014 The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer compelling commercial opportunities driven by considerable unmet need. The AD population is…
Alzheimer’s disease (AD) is one of the most common neurological conditions in the elderly and imparts considerable strain on worldwide healthcare resources. For the estimated 2 million people in…
Outpatient parenteral antimicrobial therapy (OPAT) has become a wide-spread practice in the United States. The growth of the OPAT market has been driven by its potential to reduce healthcare costs…
Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. More than half of advanced AMD patients suffer the wet (exudative, neovascular) form of the disease,…
Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have the potential to be first-line chronic obstructive pulmonary disorder (COPD) therapies…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically-important Gram-positive pathogen in both the hospital and outpatient settings. Over the past decade, the MRSA hospital market has…
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease, with rapid disease progression and high rates of mortality. As a consequence, the necessity for effective treatments are…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…